RS BioTherapeutics Revenue and Competitors

RS BioTherapeutic’s first investigational compound (RSBT-001) is a semi-synthetic, nebulized, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. Our premise is that RSBT1 provides therapeutic benefit through modulation of the Interleukin response to inflammation and modulation of alveolar macrophages responsible for fibrotic changes within the lungs. RSBT-001 is unique in that it is a polar adaptive molecule exhibiting both hydrophilic and lipophilic properties, which leads to high absorption and bioavailability enhancing therapeutic benefit.